Brief: Xencor Doses First Subject In Phase 1 Study Of Xmab®564, An Engineered Il-2 Cytokine In Development For Autoimmune Diseases
28/04/2021 22:24
April 28 (Reuters) - Xencor Inc XNCR.O :
* XENCOR DOSES FIRST SUBJECT IN PHASE 1 STUDY OF XMAB®564,
AN
ENGINEERED IL-2 CYTOKINE IN DEVELOPMENT FOR AUTOIMMUNE DISEASES
Source text for Eikon: ID:nBw5sMF9Ra
Further company coverage: XNCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xencor
See all newsXencor, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Brief: Xencor Q2 EPS USD -0.29
Brief: Xencor To Receive $105 Million From Alexion To Resolve Ultomiris® U.S. Royalty Matter
Xencor Q1 revenue falls sharply and misses estimates